2024 Mid-Year Life Sciences Insights: Highlights from the GLSA Networking Event
2024 mid-year life sciences insights were the focus of the GLSA networking event held on June 12, 2024. The Global Life Sciences Alliance (GLSA) brought together professionals from across pharma, biotech, and clinical research to reflect on market trends, industry challenges, and opportunities shaping the remainder of the year.
Opening Remarks and 2024 life Sciences Industry Updates
Chris Matheus opened the event with a warm welcome, introducing new participants and sharing timely industry updates, conference takeaways, and market observations. Attendees also shared their locations and upcoming travel plans, adding a personal and conversational element to the discussion.
Networking and Collaborative Initiatives
The meeting followed GLSA’s open-house format, encouraging participants to share LinkedIn profiles to support ongoing networking. Chris also promoted the Women of Life Sciences virtual event and invited volunteers to judge giveaways at the upcoming DIA conference. The DIA initiative is being led by Sheila Mahoney-Jewels ().
GLSA’s Mission and Conference Insights
GLSA reiterated its mission to connect people and provide solutions to challenges across the clinical trial ecosystem. Several attendees shared insights from recent industry conferences.
Michael Young, Brian Langin, Cameron Robinson, and Denise McNerney discussed takeaways from BIO, which drew more than 19,000 attendees. Michael also reviewed highlights from ASCO, noting strong attendance, a large number of first-time exhibitors, and increased engagement across oncology-focused companies.
2024 Mid-Year Market Analysis and Life Sciences Trends
Chris provided an overview of GLSA’s business activity during the first half of the year. He described an early surge in momentum followed by a noticeable slowdown in funding decisions and investor confidence.
He also discussed insights from the recent Federal Open Market Committee meeting and broader global factors influencing the market, including geopolitical tensions and the upcoming U.S. presidential election. These dynamics continue to shape decision-making across pharma and biotech.
Advances in Drug Approvals and Precision Medicine
Recent drug approvals in areas such as NASH/fatty liver disease and Alzheimer’s were highlighted as positive signals for innovation. Michael Young discussed the growing role of precision medicine in oncology, including promising technologies showcased at ASCO.
Examples included Notable Labs’ blood-based testing and Keliomics’ ex vivo tumor models. These innovations have the potential to significantly impact early-stage drug development and treatment selection.
AI and Machine Learning in Clinical Trials
Chris led a discussion on the evolving role of AI and machine learning in clinical trials. Topics included large-scale simulations, predictive modeling for patient enrollment, and AI-driven physician ranking tools.
While participants expressed optimism about the long-term potential of these technologies, many shared concerns about current limitations, particularly around patient enrollment accuracy, regulatory validation, and real-world reliability.
Patient Enrollment and Hiring Trends
The group also discussed ongoing challenges with patient enrollment in the post-COVID environment. Chris and Michael noted encouraging signs tied to the return of in-person conferences, citing strong attendance at recent events.
Lisamarie O’Brien shared insights on hiring challenges, emphasizing the need for smarter recruitment strategies and careful use of AI within applicant tracking systems.
AI in Language Translation and Budget Planning
Duncan Shaw highlighted risks associated with AI-driven language translation in clinical studies, stressing the importance of precision and accuracy. Others echoed the need for patience when evaluating AI applications in regulated environments.
Mike O’Gorman and Ira Snyder discussed limitations of AI in budget development, noting challenges related to inconsistent data quality.
Site Negotiations and Operational Challenges
Slow site contracting and competitive site selection—especially in oncology—were recurring themes. Michael Young and Jane Myles discussed delays in contract execution, while Viljena Trask emphasized the highly competitive nature of oncology site selection.
Eliana R. Burke shared a recent experience with a highly seasoned trial site, and Ira Snyder reinforced the importance of balanced negotiations to support long-term collaboration.
👉 Click here to view the 2024 Mid-year presentation.
Looking Ahead: Life Sciences Insights for the Remainder of 2024
The next GLSA networking event is scheduled for July 17, with the topic to be announced. To stay informed about future GLSA and FOCM events, be sure to sign up through the GLSA mailing list.
We look forward to continuing these conversations and seeing you at our next event.
Event Attendees
(First-time attendees in bold)
Judy Woods
Jane Myles
Viljena Trask
Bill Dirkes
Tom Lo
Lauren Sherwood
Ira Snyder
Cameron Robinson
Jared Byer
Joan Chambers
Lori Leathers
Jon Carlson
Christine Martin
Hiroki Matsushima
Duncan Shaw
Eliana Rivera Burke
Lauren Merante
Lisa Marie O’Brien
Michael Young
Marlyn Brookins
Dr. Syed Rooh ul Arifeen Naqvi
Irene Rivera
Julia Oxley
Yuko Terasawa
GLSA Team
Chris Matheus
Denise McNerney
Jim Sarene
Timmina Williams
Kelvin Izevbekhai
Rocio Rayna Reyes
About GLSA
Global Life Sciences Alliance (GLSA) connects biotechs, pharma, CROs, and clinical research sites with the right experts, advisors, and solutions to accelerate development and reduce risk. With a network of more than 200 trusted partners spanning pre-clinical and clinical research, GLSA offers flexible, cost-effective access to specialized expertise and services that support early-stage biotechs, mid-size pharma, and global pharmaceutical companies.
When you need trusted, global resources to accelerate your research, GLSA helps you scale smarter and move you forward with confidence.
To learn how GLSA can support your organization, connect with Denise McNerney or Chris Matheus for a conversation about your goals and challenges.